A year af­ter with­draw­ing IPO, Dy­nacure scraps lead drug for rare mus­cle dis­eases

The French biotech Dy­nacure is scrap­ping its lead drug af­ter run­ning in­to trou­ble dur­ing an ear­ly-stage study.

While at­tempt­ing to move from the low-dose co­hort to a high-dose in a Phase I/II study for DYN-101, the com­pa­ny ob­served el­e­vat­ed liv­er en­zyme lev­els in six pa­tients at the low­er dose, per a let­ter from CMO Chris Fre­itag to the af­fect­ed pa­tient com­mu­ni­ty. Though re­searchers tried to change the dose lev­el re­quired to move for­ward and spread out dos­ing, the com­pa­ny failed to see signs of clin­i­cal ben­e­fit and de­cid­ed to ter­mi­nate the study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER